首页> 外文期刊>British Journal of Clinical Pharmacology >Pharmacoeconomics: NICE's approach to decision-making.
【24h】

Pharmacoeconomics: NICE's approach to decision-making.

机译:药物经济学:NICE的决策方法。

获取原文
获取原文并翻译 | 示例
       

摘要

The National Institute for Health and Clinical Excellence (NICE) is a decision-maker. Where NICE reaches a positive conclusion about the use of a particular health technology (such as a pharmaceutical product) in the National Health Service (NHS), there is a legal requirement for the service to make it available if a patient's physician considers it clinically appropriate [1]. Although this legal obligation does not apply to technologies recommended in NICE'S clinical guidelines, there is still a reasonable expectation by the Care Quality Commission for NHS healthcare professionals to use NICE'S clinical guidelines as the basis, where appropriate,for their clinical practice.
机译:国家卫生与临床卓越研究所(NICE)是决策者。如果NICE在国家健康服务(NHS)中对使用特定健康技术(例如药品)得出了肯定的结论,则有法律要求,如果患者的医生认为该服务在临床上合适,则必须提供该服务[1]。尽管此法律义务不适用于NICE的临床指南中推荐的技术,但护理质量委员会仍然对NHS医护人员有合理的期望,希望在适当的情况下使用NICE的临床指南作为其临床实践的基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号